Redoxis was founded in Sweden in 2007 as a R&D spinout with focus on preclinical development of small molecules targeting molecular pathways in the immunological responses associated with autoimmune diseases. With a core expertise and background in medical inflammation research and preclinical inflammatory models we decided in 2010 to expand our activities to also encompass CRO services. The CRO activities of the company have since then grown and since spring 2016 Redoxis is focusing on CRO services while the small molecule R&D is continued in our subsidiary ProNoxis.